Showing 781 - 800 results of 41,855 for search '(( 50 ((ns decrease) OR (((mean decrease) OR (a decrease)))) ) OR ( a point decrease ))', query time: 0.90s Refine Results
  1. 781
  2. 782
  3. 783

    S-glutathionylation catalyst diamide also decreases ROS release from permeabilized skeletal muscle mitochondria. by Robert M. Gill (4854028)

    Published 2018
    “…The final concentration of pyruvate, 2-oxoglutarate, succinate, or palmitoyl-carnitine was 50 μM. n = 4, mean±SEM. (B) The decrease in mitochondrial ROS release correlates with an increase in overall protein S-glutathionylation. …”
  4. 784
  5. 785
  6. 786

    Loss of ALS2 results in decreased levels of the lysosome-dependent degradation of LC3 in fibroblasts. by Shinji Hadano (251529)

    Published 2010
    “…Fibroblasts from wild-type (WT) and <i>Als2</i><sup>−/−</sup> mice were either left unstarved (0 hr) (upper) or starved for 6 hr (lower). It is notable that a 6 hr of starvation leads to decreased levels of the LC3- and p62-immunoreactive signals in WT cells, but not in <i>Als2</i><sup>−/−</sup> cells. …”
  7. 787
  8. 788
  9. 789
  10. 790
  11. 791
  12. 792

    <i>sf3b1</i> mutant strains are defective in reproduction, development and fungi-infection resistance. by Bei Zhang (428038)

    Published 2021
    “…Fecundity was measured over a period of 12 days from females crossed with the <i>WT</i> males, and each time point represents data from ten female adults. …”
  13. 793
  14. 794
  15. 795
  16. 796

    Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension by Tetsuo Asaki (1366140)

    Published 2015
    “…Compound <b>26a</b> was developed for the treatment of pulmonary arterial hypertension and shown to reduce the risk of the composite morbidity/mortality end point in a phase 3 event-driven clinical trial.…”
  17. 797

    Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension by Tetsuo Asaki (1366140)

    Published 2015
    “…Compound <b>26a</b> was developed for the treatment of pulmonary arterial hypertension and shown to reduce the risk of the composite morbidity/mortality end point in a phase 3 event-driven clinical trial.…”
  18. 798
  19. 799
  20. 800